Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze.
- •Osoby, których stan ogólny pozwala na aktywność fizyczną (skala 0-2).
- •Osoby z potwierdzonym rozpoznaniem jednego z wymienionych typów chłoniaka.
- •Osoby, u których choroba nawróciła, nie zareagowała na poprzednie leczenie lub nie tolerują go, po co najwyżej trzech wcześniejszych terapiach ogólnoustrojowych.
- •Osoby, u których widoczne są zmiany nowotworowe w badaniach obrazowych (PET i tomografia komputerowa).
- •Osoby, u których przewidywana długość życia wynosi powyżej 12 tygodni.
- •Osoby z wystarczającą funkcją narządów, potwierdzoną przez wyniki badań krwi i moczu.
✗ Disqualifies
- •Osoby, które nie wyleczyły się całkowicie z działań niepożądanych po wcześniejszych terapiach, chyba że dotyczy to pewnych konkretnych przypadków wymienionych w pełnym protokole badania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (37)
City of Hope National Medical Center
Duarte, United States
University of California, Irvine
Irvine, United States
University of California San Francisco
San Francisco, United States
Yale University
New Haven, United States
Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine
Miami, United States
Emory University
Atlanta, United States
North Western University Robert H. Lurie Comprehensive Cancer Center RHLCCC
Chicago, United States
University of Iowa
Iowa City, United States
University of Maryland Medical Center
Baltimore, United States
Massachusetts General Hospital
Boston, United States
Roger Cancer Center University of Michigan Health
Ann Arbor, United States
Washington University in St. Louis
St Louis, United States
Hackensack University Medical Center
Hackensack, United States
Icahn School of Medicine at Mount Sinai
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Weill Cornell Medicine
New York, United States
North Carolina Cancer Hospital
Chapel Hill, United States
The Ohio State University
Columbus, United States
Oregon Health & Science University; Knight Cancer Institute
Portland, United States
University of Pittsburgh Medical Center
Pittsburgh, United States
UT Southwestern Medical Center
Dallas, United States
MD Anderson Cancer Center
Houston, United States
University of Washington Fred Hutch Cancer Center
Seattle, United States
University of Wisconsin Carbone Cancer Center
Madison, United States
St Vincent's Hospital Sydney
Darlinghurst, Australia
St George Hospital
Kogarah, Australia
ICON Cancer Centre
South Brisbane, Australia
Royal Adelaide Hospital
Adelaide, Australia
Flinders Medical Center
Bedford Park, Australia
Royal Hobart Hospital
Hobart, Australia
Box Hill Hospital
Box Hill, Australia
Austin Hospital
Heidelberg, Australia
Epworth Healthcare
Richmond, Australia
Linear Clinical Research
Perth, Australia
BC Cancer Research Institute
Vancouver, Canada
The Ottawa Hospital - General Campus
Ottawa, Canada
The Princess Margaret Cancer Centre
Toronto, Canada
Trial contact
Study Director
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.